Company intelligence / Profile preview
Primmune Therapeutics
Carlsbad, California, United Statesprimmunerx.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Published interim clinical data from the PRTX007 first-in-human study in healthy volunteers demonstrates a favorable safety profile, dose-dependent systemic exposure and activation of the innate immune response without production of proinflammatory cytokines, and breadth of immune induction with a coordinated downstream adaptive immune response[1]
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Defense Threat Reduction Agency (DTRA) - $22.5 Million Contract to advance PRTX007 for treatment of Lassa Fever[3]
Beyond the preview
Go deeper on Primmune Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Primmune Therapeutics.